Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia (Q44539672)

4 December 2017

Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia (English)

1 reference

4 December 2017

0 references

1

Raquel E Gur

1 reference

4 December 2017

8

Ruben C Gur

1 reference

4 December 2017

4

Steven J Siegel

1 reference

4 December 2017

6

James Loughead

1 reference

4 December 2017

5

Warren B Bilker

1 reference

4 December 2017

3

J Daniel Ragland

1 reference

4 December 2017

Christian Kohler

2

1 reference

4 December 2017

Nick Phend

series ordinal

7

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

4 December 2017

Neuropsychopharmacology

1 reference

4 December 2017

28

1 reference

4 December 2017

11

1 reference

4 December 2017

2029-2036

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300275

4 December 2017

0 references

cites work

Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Another view of therapy for cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Relations among clinical scales in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Computerized neurocognitive scanning: II. The profile of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Computerized neurocognitive scanning: I. Methodology and validation in healthy people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Emotion recognition deficit in schizophrenia: association with symptomatology and cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Visual object working memory function and clinical symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Olanzapine versus haloperidol treatment in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

A rating scale for tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

The prediction of outcome in schizophrenia. I. Characteristics of outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Visuospatial memory and learning in first-episode schizophreniform psychosis and established schizophrenia: a functional correlate of hippocampal pathology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

inferred from DOI database lookup

7 January 2021

based on heuristic

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

inferred from DOI database lookup

7 January 2021

based on heuristic

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300275

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.NPP.1300275

0 references

1 reference